Listed

Eloxx Pharmaceuticals, Inc.

ELOXNasdaqCIK 1035354HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$4.5m, Q2 FY2026
Net income−$4.5m, Q2 FY2026
Eloxx Pharmaceuticals, Inc., income statement, quarterly
Line itemUnitQ1 FY20222022-03-31Q2 FY20222022-06-30Q3 FY20222022-09-30Q4 FY20222022-12-31Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30period not labelled2023-12-31period not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Operating income$m(11.0)Operating income, Q1 FY2022, three months to 2022-03-31−$11.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure(10.3)Operating income, Q2 FY2022, three months to 2022-06-30−$10.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2023-08-11, accession 0000950170-23-041837.Report this figure(7.1)Operating income, Q3 FY2022, three months to 2022-09-30−$7.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure(6.0)Operating income, Q4 FY2022, three months to 2022-12-31−$6.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-03-31, accession 0000950170-23-011360. Derived: 12-month figure less the 9-month figure.Report this figure(5.5)Operating income, Q1 FY2023, three months to 2023-03-31−$5.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure(4.1)Operating income, Q2 FY2023, three months to 2023-06-30−$4.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2023-08-11, accession 0000950170-23-041837.Report this figure(3.6)Operating income, Q3 FY2023, three months to 2023-09-30−$3.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure(4.0)Operating income, period not labelled, three months to 2023-12-31−$4.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-17, accession 0001193125-26-108687. Derived: 12-month figure less the 9-month figure.Report this figure(1.2)Operating income, period not labelled, three months to 2025-03-31−$1.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001193125-26-204722.Report this figure(1.6)Operating income, period not labelled, three months to 2025-06-30−$1.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure(3.8)Operating income, Q1 FY2026, three months to 2026-03-31−$3.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001193125-26-204722.Report this figure(4.5)Operating income, Q2 FY2026, three months to 2026-06-30−$4.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(11.6)Net income, Q1 FY2022, three months to 2022-03-31−$11.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure(10.6)Net income, Q2 FY2022, three months to 2022-06-30−$10.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure(7.5)Net income, Q3 FY2022, three months to 2022-09-30−$7.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure(6.3)Net income, Q4 FY2022, three months to 2022-12-31−$6.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-03-31, accession 0000950170-23-011360. Derived: 12-month figure less the 9-month figure.Report this figure(6.2)Net income, Q1 FY2023, three months to 2023-03-31−$6.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure(4.3)Net income, Q2 FY2023, three months to 2023-06-30−$4.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure(3.6)Net income, Q3 FY2023, three months to 2023-09-30−$3.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure(2.9)Net income, period not labelled, three months to 2023-12-31−$2.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-17, accession 0001193125-26-108687. Derived: 12-month figure less the 9-month figure.Report this figure(1.7)Net income, period not labelled, three months to 2025-03-31−$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure(1.9)Net income, period not labelled, three months to 2025-06-30−$1.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure(3.8)Net income, Q1 FY2026, three months to 2026-03-31−$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure(4.5)Net income, Q2 FY2026, three months to 2026-06-30−$4.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure
Diluted EPS$ per share(5.36)Diluted EPS, Q1 FY2022, three months to 2022-03-31−$5.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure(4.90)Diluted EPS, Q2 FY2022, three months to 2022-06-30−$4.90 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2023-08-11, accession 0000950170-23-041837.Report this figure(3.47)Diluted EPS, Q3 FY2022, three months to 2022-09-30−$3.47 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figurenot reported(2.88)Diluted EPS, Q1 FY2023, three months to 2023-03-31−$2.88 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure(1.96)Diluted EPS, Q2 FY2023, three months to 2023-06-30−$1.96 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2023-08-11, accession 0000950170-23-041837.Report this figure(1.31)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$1.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figurenot reported(0.45)Diluted EPS, period not labelled, three months to 2025-03-31−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001193125-26-204722.Report this figure(5.45)Diluted EPS, period not labelled, three months to 2025-06-30−$5.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure(0.08)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001193125-26-204722.Report this figure(0.66)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.66 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure
Basic EPS$ per share(5.36)Basic EPS, Q1 FY2022, three months to 2022-03-31−$5.36 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure(4.90)Basic EPS, Q2 FY2022, three months to 2022-06-30−$4.90 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2023-08-11, accession 0000950170-23-041837.Report this figure(3.47)Basic EPS, Q3 FY2022, three months to 2022-09-30−$3.47 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figurenot reported(2.88)Basic EPS, Q1 FY2023, three months to 2023-03-31−$2.88 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure(1.96)Basic EPS, Q2 FY2023, three months to 2023-06-30−$1.96 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2023-08-11, accession 0000950170-23-041837.Report this figure(1.31)Basic EPS, Q3 FY2023, three months to 2023-09-30−$1.31 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figurenot reported(0.45)Basic EPS, period not labelled, three months to 2025-03-31−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-05, accession 0001193125-26-204722.Report this figure(5.45)Basic EPS, period not labelled, three months to 2025-06-30−$5.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure(0.08)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.08 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-05, accession 0001193125-26-204722.Report this figure(0.66)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.66 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure

Balance sheet

Cash and equivalents$62.0m, Q2 FY2026
Long-term debt$0, FY2025
Shareholders' equity$46.4m, Q2 FY2026
Eloxx Pharmaceuticals, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20222022-09-30FY20222022-12-31Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30period not labelled2023-12-31period not labelled2024-12-31period not labelled2025-03-31period not labelled2025-06-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m24.6Cash and equivalents, Q3 FY2022, at 2022-09-30$24.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure19.2Cash and equivalents, FY2022, at 2022-12-31$19.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure4.9Cash and equivalents, Q1 FY2023, at 2023-03-31$4.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure4.3Cash and equivalents, Q2 FY2023, at 2023-06-30$4.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-08-11, accession 0000950170-23-041837.Report this figure4.8Cash and equivalents, Q3 FY2023, at 2023-09-30$4.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure1.1Cash and equivalents, period not labelled, at 2023-12-31$1.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-17, accession 0001193125-26-108687.Report this figure0.1Cash and equivalents, period not labelled, at 2024-12-31$111.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-17, accession 0001193125-26-108687.Report this figure0.5Cash and equivalents, period not labelled, at 2025-03-31$450.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-05, accession 0001193125-26-204722.Report this figure0.6Cash and equivalents, period not labelled, at 2025-06-30$572.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure4.8Cash and equivalents, FY2025, at 2025-12-31$4.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure6.4Cash and equivalents, Q1 FY2026, at 2026-03-31$6.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-05, accession 0001193125-26-204722.Report this figure62.0Cash and equivalents, Q2 FY2026, at 2026-06-30$62.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure
Current assets$m25.7Current assets, Q3 FY2022, at 2022-09-30$25.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2022-11-10, accession 0000950170-22-024490.Report this figure20.1Current assets, FY2022, at 2022-12-31$20.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure6.4Current assets, Q1 FY2023, at 2023-03-31$6.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure5.4Current assets, Q2 FY2023, at 2023-06-30$5.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-08-11, accession 0000950170-23-041837.Report this figure5.6Current assets, Q3 FY2023, at 2023-09-30$5.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure1.5Current assets, period not labelled, at 2023-12-31$1.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-17, accession 0001193125-26-108687.Report this figure3.0Current assets, period not labelled, at 2024-12-31$3.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-17, accession 0001193125-26-108687.Report this figurenot reportednot reported5.3Current assets, FY2025, at 2025-12-31$5.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure8.5Current assets, Q1 FY2026, at 2026-03-31$8.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-05, accession 0001193125-26-204722.Report this figure63.4Current assets, Q2 FY2026, at 2026-06-30$63.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure
Total assets$m26.9Total assets, Q3 FY2022, at 2022-09-30$26.9m. XBRL concept us-gaap:Assets. 10-Q filed 2022-11-10, accession 0000950170-22-024490.Report this figure21.1Total assets, FY2022, at 2022-12-31$21.1m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure7.2Total assets, Q1 FY2023, at 2023-03-31$7.2m. XBRL concept us-gaap:Assets. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure6.0Total assets, Q2 FY2023, at 2023-06-30$6.0m. XBRL concept us-gaap:Assets. 10-Q filed 2023-08-11, accession 0000950170-23-041837.Report this figure6.0Total assets, Q3 FY2023, at 2023-09-30$6.0m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure1.7Total assets, period not labelled, at 2023-12-31$1.7m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-17, accession 0001193125-26-108687.Report this figure3.0Total assets, period not labelled, at 2024-12-31$3.0m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-17, accession 0001193125-26-108687.Report this figurenot reportednot reported5.3Total assets, FY2025, at 2025-12-31$5.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure8.5Total assets, Q1 FY2026, at 2026-03-31$8.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-05, accession 0001193125-26-204722.Report this figure63.4Total assets, Q2 FY2026, at 2026-06-30$63.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure
Current liabilities$m21.7Current liabilities, Q3 FY2022, at 2022-09-30$21.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2022-11-10, accession 0000950170-22-024490.Report this figure23.1Current liabilities, FY2022, at 2022-12-31$23.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure19.5Current liabilities, Q1 FY2023, at 2023-03-31$19.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure21.3Current liabilities, Q2 FY2023, at 2023-06-30$21.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-08-11, accession 0000950170-23-041837.Report this figure23.5Current liabilities, Q3 FY2023, at 2023-09-30$23.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure22.7Current liabilities, period not labelled, at 2023-12-31$22.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-17, accession 0001193125-26-108687.Report this figure27.3Current liabilities, period not labelled, at 2024-12-31$27.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-17, accession 0001193125-26-108687.Report this figurenot reportednot reported17.2Current liabilities, FY2025, at 2025-12-31$17.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure16.1Current liabilities, Q1 FY2026, at 2026-03-31$16.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-05, accession 0001193125-26-204722.Report this figure17.0Current liabilities, Q2 FY2026, at 2026-06-30$17.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure
Total liabilities$m31.9Total liabilities, Q3 FY2022, at 2022-09-30$31.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2022-11-10, accession 0000950170-22-024490.Report this figure31.8Total liabilities, FY2022, at 2022-12-31$31.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure23.5Total liabilities, Q1 FY2023, at 2023-03-31$23.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure24.6Total liabilities, Q2 FY2023, at 2023-06-30$24.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-08-11, accession 0000950170-23-041837.Report this figure26.1Total liabilities, Q3 FY2023, at 2023-09-30$26.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure24.3Total liabilities, period not labelled, at 2023-12-31$24.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-17, accession 0001193125-26-108687.Report this figure27.3Total liabilities, period not labelled, at 2024-12-31$27.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-17, accession 0001193125-26-108687.Report this figurenot reportednot reported17.2Total liabilities, FY2025, at 2025-12-31$17.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-17, accession 0001193125-26-108687.Report this figurenot reportednot reported
Long-term debt$m9.9Long-term debt, Q3 FY2022, at 2022-09-30$9.9m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2022-11-10, accession 0000950170-22-024490.Report this figure8.6Long-term debt, FY2022, at 2022-12-31$8.6m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure4.0Long-term debt, Q1 FY2023, at 2023-03-31$4.0m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure3.3Long-term debt, Q2 FY2023, at 2023-06-30$3.3m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2023-08-11, accession 0000950170-23-041837.Report this figure2.6Long-term debt, Q3 FY2023, at 2023-09-30$2.6m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure1.6Long-term debt, period not labelled, at 2023-12-31$1.6m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-K filed 2026-03-17, accession 0001193125-26-108687.Report this figure0.0Long-term debt, period not labelled, at 2024-12-31$0. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-K filed 2026-03-17, accession 0001193125-26-108687.Report this figurenot reportednot reported0.0Long-term debt, FY2025, at 2025-12-31$0. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-K filed 2026-03-17, accession 0001193125-26-108687.Report this figurenot reportednot reported
Current portion of debt$m2.5Current portion of debt, Q3 FY2022, at 2022-09-30$2.5m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2022-11-10, accession 0000950170-22-024490.Report this figure4.0Current portion of debt, FY2022, at 2022-12-31$4.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure1.5Current portion of debt, Q1 FY2023, at 2023-03-31$1.5m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure2.3Current portion of debt, Q2 FY2023, at 2023-06-30$2.3m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2023-08-11, accession 0000950170-23-041837.Report this figure2.8Current portion of debt, Q3 FY2023, at 2023-09-30$2.8m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure2.2Current portion of debt, period not labelled, at 2023-12-31$2.2m. XBRL concept us-gaap:LongTermDebtCurrent. 10-K filed 2026-03-17, accession 0001193125-26-108687.Report this figure6.5Current portion of debt, period not labelled, at 2024-12-31$6.5m. XBRL concept us-gaap:LongTermDebtCurrent. 10-K filed 2026-03-17, accession 0001193125-26-108687.Report this figurenot reportednot reported1.0Current portion of debt, FY2025, at 2025-12-31$1.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure0.0Current portion of debt, Q1 FY2026, at 2026-03-31$0. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-05-05, accession 0001193125-26-204722.Report this figure0.0Current portion of debt, Q2 FY2026, at 2026-06-30$0. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure
Shareholders' equity$m(5.0)Shareholders' equity, Q3 FY2022, at 2022-09-30−$5.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure(10.7)Shareholders' equity, FY2022, at 2022-12-31−$10.7m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-17, accession 0001193125-26-108687.Report this figure16.3Shareholders' equity, Q1 FY2023, at 2023-03-31$16.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure(18.6)Shareholders' equity, Q2 FY2023, at 2023-06-30−$18.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure(20.0)Shareholders' equity, Q3 FY2023, at 2023-09-30−$20.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure(22.6)Shareholders' equity, period not labelled, at 2023-12-31−$22.6m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-17, accession 0001193125-26-108687.Report this figure(24.3)Shareholders' equity, period not labelled, at 2024-12-31−$24.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure(26.0)Shareholders' equity, period not labelled, at 2025-03-31−$26.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure(27.9)Shareholders' equity, period not labelled, at 2025-06-30−$27.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure(11.9)Shareholders' equity, FY2025, at 2025-12-31−$11.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure(7.6)Shareholders' equity, Q1 FY2026, at 2026-03-31−$7.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure46.4Shareholders' equity, Q2 FY2026, at 2026-06-30$46.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure

Cash flow

Operating cash flow−$4.8m, Q2 FY2026
Capital expenditure$0, Q3 FY2023
Eloxx Pharmaceuticals, Inc., cash flow, quarterly
Line itemUnitQ1 FY20222022-03-31Q2 FY20222022-06-30Q3 FY20222022-09-30Q4 FY20222022-12-31Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30period not labelled2023-12-31period not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(9,491)Operating cash flow, Q1 FY2022, three months to 2022-03-31−$9.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure(9,747)Operating cash flow, Q2 FY2022, three months to 2022-06-30−$9.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2023-08-11, accession 0000950170-23-041837. Derived: 6-month figure less the 3-month figure.Report this figure(6,946)Operating cash flow, Q3 FY2022, three months to 2022-09-30−$6.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2023-11-13, accession 0000950170-23-062940. Derived: 9-month figure less the 6-month figure.Report this figure(5,661)Operating cash flow, Q4 FY2022, three months to 2022-12-31−$5.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-31, accession 0000950170-23-011360. Derived: 12-month figure less the 9-month figure.Report this figure(6,814)Operating cash flow, Q1 FY2023, three months to 2023-03-31−$6.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure(2,066)Operating cash flow, Q2 FY2023, three months to 2023-06-30−$2.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2023-08-11, accession 0000950170-23-041837. Derived: 6-month figure less the 3-month figure.Report this figure(3,450)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$3.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2023-11-13, accession 0000950170-23-062940. Derived: 9-month figure less the 6-month figure.Report this figure(2,011)Operating cash flow, period not labelled, three months to 2023-12-31−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-17, accession 0001193125-26-108687. Derived: 12-month figure less the 9-month figure.Report this figure1,204Operating cash flow, period not labelled, three months to 2025-03-31$1.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001193125-26-204722.Report this figure(1,753)Operating cash flow, period not labelled, three months to 2025-06-30−$1.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-344964. Derived: 6-month figure less the 3-month figure.Report this figure(5,453)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$5.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001193125-26-204722.Report this figure(4,789)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$4.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-344964. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$k11.0Capital expenditure, Q1 FY2022, three months to 2022-03-31$11.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure7.0Capital expenditure, Q2 FY2022, three months to 2022-06-30$7.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2023-08-11, accession 0000950170-23-041837. Derived: 6-month figure less the 3-month figure.Report this figure48.0Capital expenditure, Q3 FY2022, three months to 2022-09-30$48.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2023-11-13, accession 0000950170-23-062940. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2022, three months to 2022-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-31, accession 0000950170-23-011360. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2023, three months to 2023-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure0.0Capital expenditure, Q2 FY2023, three months to 2023-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2023-08-11, accession 0000950170-23-041837. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2023-11-13, accession 0000950170-23-062940. Derived: 9-month figure less the 6-month figure.Report this figurenot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)6.79m, Q2 FY2026
Eloxx Pharmaceuticals, Inc., shares, quarterly
Line itemUnitQ2 FY20212021-06-30Q3 FY20212021-09-30Q1 FY20222022-03-31Q2 FY20222022-06-30Q3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30period not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares66.4Diluted shares (weighted), Q2 FY2021, three months to 2021-06-3066,389,865 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2022-08-12, accession 0001564590-22-029339.Report this figure86.2Diluted shares (weighted), Q3 FY2021, three months to 2021-09-3086,208,754 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2022-11-10, accession 0000950170-22-024490.Report this figure2.2Diluted shares (weighted), Q1 FY2022, three months to 2022-03-312,166,275 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure2.2Diluted shares (weighted), Q2 FY2022, three months to 2022-06-302,166,352 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-08-11, accession 0000950170-23-041837.Report this figure2.2Diluted shares (weighted), Q3 FY2022, three months to 2022-09-302,166,404 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure2.2Diluted shares (weighted), Q1 FY2023, three months to 2023-03-312,166,356 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-05-12, accession 0000950170-23-021821.Report this figure2.2Diluted shares (weighted), Q2 FY2023, three months to 2023-06-302,212,364 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-08-11, accession 0000950170-23-041837.Report this figure2.7Diluted shares (weighted), Q3 FY2023, three months to 2023-09-302,747,687 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-13, accession 0000950170-23-062940.Report this figure3.8Diluted shares (weighted), period not labelled, three months to 2025-03-313,805,550 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-05, accession 0001193125-26-204722.Report this figure0.3Diluted shares (weighted), period not labelled, three months to 2025-06-30347,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure48.2Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3148,210,071 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-05, accession 0001193125-26-204722.Report this figure6.8Diluted shares (weighted), Q2 FY2026, three months to 2026-06-306,789,165 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure

Shares outstanding: 4.04mShares outstanding, period not labelled, at 2026-08-074,036,459 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344964.Report this figure at Aug 7, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. Listed shows no prices and gives no investment advice.